EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction

Background: Heart failure with preserved ejection fraction (HFpEF) is a complex disease which accounts for more than half of all HF hospital admissions with high prevalence and lack of effective evidence-based management. Sodium-glucose cotransporter 2 (SGLT2) inhibitor is a new antidiabetic drug th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagdy, Kerolos, Nagy, Sherif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Magdi Yacoub Heart Foundation 2021
Materias:
Lessons from the Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587377/
https://www.ncbi.nlm.nih.gov/pubmed/34805375
http://dx.doi.org/10.21542/gcsp.2021.17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587377/
https://www.ncbi.nlm.nih.gov/pubmed/34805375
http://dx.doi.org/10.21542/gcsp.2021.17

Ejemplares similares